MX357213B - Anticuerpo de antagonista especifico de heterodimero alfa-4-beta-7. - Google Patents
Anticuerpo de antagonista especifico de heterodimero alfa-4-beta-7.Info
- Publication number
- MX357213B MX357213B MX2016001889A MX2016001889A MX357213B MX 357213 B MX357213 B MX 357213B MX 2016001889 A MX2016001889 A MX 2016001889A MX 2016001889 A MX2016001889 A MX 2016001889A MX 357213 B MX357213 B MX 357213B
- Authority
- MX
- Mexico
- Prior art keywords
- beta
- alpha
- antagonist antibody
- specific antagonist
- heterodimer specific
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
Abstract
La presente invención se refiere a el uso de una composición que comprende: a) una proteína de unión a antígeno específica de heterodímero alfa4beta7seleccionada del grupo que consiste de: (i) una proteína de unión a antígeno específico de heterodímero alfa4beta7 que tiene una región variable de cadena pesada que comprende CDR1 CDR2 y CDR3 de SEQ ID NO: 37, y una región variable de cadena ligera que comprende CDR1, CDR2y CDR3 de SEQ ID NO: 9; (ii) una proteína de unión a antígeno específico de heterodímero alfa4beta7 en donde la región variable de cadena ligera es al menos 90% idéntica a la SEC ID NO: 9, y la región variable de cadena pesada es al menos 90% idéntica a la SEC ID BNO: 37; Y (iii) una proteína de unión a antígeno específico de heterodímero alfa4beta7 en donde la región variable de cadena ligera comprende la SEC ID NO: 9, y la región variable de cadena se selecciona del grupo que consiste de un polipéptido que comprende la SEC ID NO: 37 y un polipéptido que comprende la SEC ID NO: 37, en donde el aminiácido N-terminal se convierte en ácido piroglutámico; y (b) un diluyente, excipiente o portador fisiológicamente aceptable, para la manufactura de un medicamento para el tratamiento de una condición caracterizada por tráfico de células que expresan alfa4beta7 a tejidos que comprende células que expresan MAdCAm-1, en donde la condición es enfermedad inflamatoria de intestino.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16215409P | 2009-03-20 | 2009-03-20 | |
| US30682910P | 2010-02-22 | 2010-02-22 | |
| PCT/US2010/027422 WO2010107752A2 (en) | 2009-03-20 | 2010-03-16 | Alpha-4-beta-7 heterodimer specific antagonist antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX357213B true MX357213B (es) | 2018-06-29 |
Family
ID=42224952
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016001889A MX357213B (es) | 2009-03-20 | 2010-03-16 | Anticuerpo de antagonista especifico de heterodimero alfa-4-beta-7. |
| MX2015002115A MX338969B (es) | 2009-03-20 | 2010-03-16 | Anticuerpo de antagonista especifico de heterodimero alfa-4-beta-7. |
| MX2011009897A MX2011009897A (es) | 2009-03-20 | 2010-03-16 | Anticuerpo de antagonista especifico de heterodimero alfa-4-beta-7. |
| MX2014013424A MX357211B (es) | 2009-03-20 | 2010-03-16 | Anticuerpo de antagonista especifico de heterodimero alfa-4-beta-7. |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015002115A MX338969B (es) | 2009-03-20 | 2010-03-16 | Anticuerpo de antagonista especifico de heterodimero alfa-4-beta-7. |
| MX2011009897A MX2011009897A (es) | 2009-03-20 | 2010-03-16 | Anticuerpo de antagonista especifico de heterodimero alfa-4-beta-7. |
| MX2014013424A MX357211B (es) | 2009-03-20 | 2010-03-16 | Anticuerpo de antagonista especifico de heterodimero alfa-4-beta-7. |
Country Status (27)
| Country | Link |
|---|---|
| US (6) | US8444981B2 (es) |
| EP (1) | EP2408816B1 (es) |
| JP (3) | JP5498566B2 (es) |
| KR (2) | KR101391472B1 (es) |
| CN (2) | CN102388068B (es) |
| AR (1) | AR075882A1 (es) |
| AU (1) | AU2010226814B2 (es) |
| CA (2) | CA2851737C (es) |
| CL (3) | CL2011002306A1 (es) |
| CO (1) | CO6501170A2 (es) |
| CR (1) | CR20110544A (es) |
| EA (1) | EA034783B1 (es) |
| ES (1) | ES2751946T3 (es) |
| HK (1) | HK1168116A1 (es) |
| IL (4) | IL214868A (es) |
| JO (1) | JO3615B1 (es) |
| MA (1) | MA33213B1 (es) |
| MX (4) | MX357213B (es) |
| MY (2) | MY162752A (es) |
| NZ (1) | NZ595464A (es) |
| PE (2) | PE20120497A1 (es) |
| SG (3) | SG174344A1 (es) |
| TN (1) | TN2011000433A1 (es) |
| TW (2) | TWI466681B (es) |
| UY (1) | UY32501A (es) |
| WO (1) | WO2010107752A2 (es) |
| ZA (1) | ZA201107279B (es) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108969469A (zh) * | 2011-05-02 | 2018-12-11 | 米伦纽姆医药公司 | 抗α4β7抗体的制剂 |
| UA116189C2 (uk) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| EP2782599B1 (en) * | 2011-11-23 | 2019-10-16 | Amgen Inc. | Administration of alpha4beta7 hetero-dimer-specific antibody |
| DK3489261T3 (da) | 2012-08-24 | 2020-12-14 | Univ California | Antistoffer og vacciner til anvendelse ved behandling af ror1-cancere og hæmning af metastase |
| UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| US9708375B2 (en) | 2013-03-15 | 2017-07-18 | Amgen Inc. | Inhibitory polypeptides specific to WNT inhibitors |
| AU2014318017B2 (en) | 2013-09-05 | 2020-02-06 | Amgen Inc. | Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles |
| PT3112462T (pt) * | 2014-02-28 | 2019-02-08 | Astellas Pharma Inc | Novos anticorpos biespecíficos ligando a tlr2 humano e tlr4 humano |
| EP3143404B1 (en) | 2014-05-16 | 2018-08-29 | Amgen Inc. | Assay for detecting th1 and th2 cell populations |
| WO2016028523A2 (en) | 2014-08-22 | 2016-02-25 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind cxcr3 |
| EP3204424B1 (en) | 2014-10-06 | 2023-11-29 | ChemoCentryx, Inc. | Combination therapy of c-c chemokine receptor-9 (ccr9) inhibitors and anti-alpha4beta7 integrin blocking antibodies for the treatment of inflammatory bowel disease |
| EP3581585A1 (en) | 2014-11-26 | 2019-12-18 | Millennium Pharmaceuticals, Inc. | Vedolizumab for the treatment of fistulizing crohn's disease |
| MA41636A (fr) | 2015-03-06 | 2018-01-09 | Millennium Pharm Inc | Méthode de traitement de la cholangite sclérosante primitive |
| CA2994412A1 (en) * | 2015-07-31 | 2017-02-09 | Memorial Sloan-Kettering Cancer Center | Antigen-binding proteins targeting cd56 and uses thereof |
| SG11201800864XA (en) * | 2015-08-11 | 2018-03-28 | Univ Osaka | Antibody |
| JP2019512493A (ja) | 2016-03-14 | 2019-05-16 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 移植片対宿主病の処置または予防の方法 |
| CN116327920A (zh) * | 2016-03-14 | 2023-06-27 | 千禧制药公司 | 预防移植物抗宿主疾病的方法 |
| KR102039189B1 (ko) * | 2016-03-23 | 2019-11-01 | 서울대학교산학협력단 | 중증열성혈소판감소증후군 바이러스의 외막 당단백질에 결합하는 항체 및 이의 용도 |
| WO2017165742A1 (en) | 2016-03-24 | 2017-09-28 | Millennium Pharmaceuticals, Inc. | Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments |
| EP3433275A1 (en) | 2016-03-24 | 2019-01-30 | Millennium Pharmaceuticals, Inc. | Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments |
| WO2017184619A2 (en) | 2016-04-18 | 2017-10-26 | Celldex Therapeutics, Inc. | Agonistic antibodies that bind human cd40 and uses thereof |
| CN109414502A (zh) | 2016-06-12 | 2019-03-01 | 千禧制药公司 | 治疗炎症性肠病的方法 |
| WO2018005519A2 (en) | 2016-06-27 | 2018-01-04 | The Regents Of The University Of California | Cancer treatment combinations |
| EP3596225A1 (en) | 2017-03-14 | 2020-01-22 | Amgen Inc. | Control of total afucosylated glycoforms of antibodies produced in cell culture |
| KR20190141148A (ko) | 2017-04-28 | 2019-12-23 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 소아 장애를 치료하는 방법 |
| CN111954719A (zh) | 2018-03-26 | 2020-11-17 | 美国安进公司 | 细胞培养物中产生的抗体的总去岩藻糖基化糖型 |
| AU2020355251A1 (en) | 2019-09-26 | 2022-04-21 | Amgen Inc. | Methods of producing antibody compositions |
| AU2021227687B2 (en) | 2020-02-26 | 2023-02-23 | Vir Biotechnology, Inc. | Antibodies against SARS-CoV-2 and methods of using the same |
| US20230273126A1 (en) | 2020-06-04 | 2023-08-31 | Amgen Inc. | Assessment of cleaning procedures of a biotherapeutic manufacturing process |
| CA3197930A1 (en) | 2020-10-15 | 2022-04-21 | Amgen Inc. | Relative unpaired glycans in antibody production methods |
| MX2023010340A (es) * | 2021-03-12 | 2024-01-12 | Icahn School Med Mount Sinai | Anticuerpos monoclonales neutralizantes de virus bk. |
| EP4352094A1 (en) | 2021-06-07 | 2024-04-17 | Amgen Inc. | Using fucosidase to control afucosylation level of glycosylated proteins |
| CA3233279A1 (en) | 2021-10-05 | 2023-04-13 | Amgen Inc. | Fc-gamma receptor ii binding and glycan content |
| WO2023215725A1 (en) | 2022-05-02 | 2023-11-09 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US714785A (en) | 1901-07-03 | 1902-12-02 | Benjamin M Davis | Disinfecting apparatus. |
| US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5011912A (en) | 1986-12-19 | 1991-04-30 | Immunex Corporation | Hybridoma and monoclonal antibody for use in an immunoaffinity purification system |
| US6010902A (en) | 1988-04-04 | 2000-01-04 | Bristol-Meyers Squibb Company | Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| JP2938569B2 (ja) | 1990-08-29 | 1999-08-23 | ジェンファーム インターナショナル，インコーポレイティド | 異種免疫グロブリンを作る方法及びトランスジェニックマウス |
| ATE160379T1 (de) | 1990-10-29 | 1997-12-15 | Chiron Corp | Bispezifische antikörper, verfahren zu ihrer herstellung und deren verwendungen |
| US5582996A (en) | 1990-12-04 | 1996-12-10 | The Wistar Institute Of Anatomy & Biology | Bifunctional antibodies and method of preparing same |
| DE4118120A1 (de) | 1991-06-03 | 1992-12-10 | Behringwerke Ag | Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| ATE255131T1 (de) | 1991-06-14 | 2003-12-15 | Genentech Inc | Humanisierter heregulin antikörper |
| US5262522A (en) | 1991-11-22 | 1993-11-16 | Immunex Corporation | Receptor for oncostatin M and leukemia inhibitory factor |
| JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化ｂ−ｂ１０ |
| US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
| AU678787B2 (en) | 1992-10-23 | 1997-06-12 | Immunex Corporation | Methods of preparing soluble, oligomeric proteins |
| US5457035A (en) | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
| JP4115517B2 (ja) | 1994-01-25 | 2008-07-09 | エラン ファーマシューティカルズ， インコーポレイテッド | 白血球付着分子 ｖｌａ−４に対するヒト化抗体 |
| US5840299A (en) | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
| US7435802B2 (en) * | 1994-01-25 | 2008-10-14 | Elan Pharaceuticals, Inc. | Humanized anti-VLA4 immunoglobulins |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US7147851B1 (en) * | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| US20020142374A1 (en) | 1998-08-17 | 2002-10-03 | Michael Gallo | Generation of modified molecules with increased serum half-lives |
| AU7676300A (en) * | 1999-10-12 | 2001-04-23 | Cambridge Antibody Technology Limited | Human anti-adipocyte monoclonal antibodies and their use |
| GB9928787D0 (en) | 1999-12-03 | 2000-02-02 | Medical Res Council | Direct screening method |
| US20010046496A1 (en) * | 2000-04-14 | 2001-11-29 | Brettman Lee R. | Method of administering an antibody |
| GB0025144D0 (en) | 2000-10-13 | 2000-11-29 | Medical Res Council | Concatenated nucleic acid sequences |
| WO2002076406A2 (en) * | 2001-03-27 | 2002-10-03 | Gershwin M Eric | Antibodies against autoantigens of primary biliary cirrhosis and methods of making and using them |
| WO2002078779A1 (fr) * | 2001-03-27 | 2002-10-10 | Zeon Corporation | Fil-guide medical |
| US20030191056A1 (en) | 2002-04-04 | 2003-10-09 | Kenneth Walker | Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins |
| EP1542724A4 (en) * | 2002-08-19 | 2005-10-19 | Abgenix Inc | ANTIBODIES AGAINST THE MONOCYTE 1 CHIMIOATTRACTIVE PROTEIN (MCP-1) AND USES THEREOF |
| US20040202995A1 (en) | 2003-04-09 | 2004-10-14 | Domantis | Nucleic acids, proteins, and screening methods |
| MX350383B (es) * | 2004-01-09 | 2017-09-04 | Pfizer | Anticuerpos contra madcam. |
| WO2006017538A2 (en) * | 2004-08-03 | 2006-02-16 | Dyax Corp. | Hk1-binding proteins |
| US20070098715A1 (en) | 2005-03-25 | 2007-05-03 | Seth Ettenberg | Antibodies against the tenascin major antigens |
| US7480268B2 (en) | 2005-07-28 | 2009-01-20 | Symbol Technologies, Inc. | System and method for multiprotocol wireless communication |
| CA2629147A1 (en) * | 2005-11-17 | 2007-05-31 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with .alpha.4.beta.7 integrin |
| US7910703B2 (en) * | 2006-03-10 | 2011-03-22 | Zymogenetics, Inc. | Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use |
-
2010
- 2010-03-16 SG SG2011065570A patent/SG174344A1/en unknown
- 2010-03-16 TW TW99107689A patent/TWI466681B/zh active
- 2010-03-16 KR KR1020137012483A patent/KR101391472B1/ko active IP Right Grant
- 2010-03-16 EP EP10708688.6A patent/EP2408816B1/en active Active
- 2010-03-16 ES ES10708688T patent/ES2751946T3/es active Active
- 2010-03-16 MA MA34274A patent/MA33213B1/fr unknown
- 2010-03-16 TW TW103102822A patent/TWI477511B/zh active
- 2010-03-16 MX MX2016001889A patent/MX357213B/es unknown
- 2010-03-16 NZ NZ595464A patent/NZ595464A/xx unknown
- 2010-03-16 WO PCT/US2010/027422 patent/WO2010107752A2/en active Application Filing
- 2010-03-16 AU AU2010226814A patent/AU2010226814B2/en active Active
- 2010-03-16 EA EA201171148A patent/EA034783B1/ru not_active IP Right Cessation
- 2010-03-16 SG SG10201400798VA patent/SG10201400798VA/en unknown
- 2010-03-16 CN CN201080013557.9A patent/CN102388068B/zh active Active
- 2010-03-16 KR KR1020117024649A patent/KR101346530B1/ko active IP Right Grant
- 2010-03-16 MY MYPI2011004308A patent/MY162752A/en unknown
- 2010-03-16 MX MX2015002115A patent/MX338969B/es unknown
- 2010-03-16 CA CA2851737A patent/CA2851737C/en active Active
- 2010-03-16 JP JP2012500875A patent/JP5498566B2/ja active Active
- 2010-03-16 MY MYPI2015002744A patent/MY184957A/en unknown
- 2010-03-16 SG SG10201801337WA patent/SG10201801337WA/en unknown
- 2010-03-16 PE PE2011001661A patent/PE20120497A1/es not_active Application Discontinuation
- 2010-03-16 PE PE2016000333A patent/PE20160553A1/es unknown
- 2010-03-16 CA CA2754113A patent/CA2754113C/en active Active
- 2010-03-16 US US12/725,031 patent/US8444981B2/en active Active
- 2010-03-16 MX MX2011009897A patent/MX2011009897A/es active IP Right Grant
- 2010-03-16 MX MX2014013424A patent/MX357211B/es active IP Right Grant
- 2010-03-16 CN CN201310216898.1A patent/CN103382222B/zh active Active
- 2010-03-18 JO JOP/2010/0090A patent/JO3615B1/ar active
- 2010-03-18 AR ARP100100867A patent/AR075882A1/es active IP Right Grant
- 2010-03-18 UY UY0001032501A patent/UY32501A/es not_active Application Discontinuation
-
2011
- 2011-08-24 TN TN2011000433A patent/TN2011000433A1/fr unknown
- 2011-08-29 IL IL214868A patent/IL214868A/en active IP Right Grant
- 2011-09-16 CL CL2011002306A patent/CL2011002306A1/es unknown
- 2011-09-30 CO CO11128767A patent/CO6501170A2/es not_active Application Discontinuation
- 2011-10-05 ZA ZA2011/07279A patent/ZA201107279B/en unknown
- 2011-10-18 CR CR20110544A patent/CR20110544A/es unknown
-
2012
- 2012-03-22 US US13/427,745 patent/US8454961B2/en not_active Expired - Fee Related
- 2012-03-22 US US13/427,757 patent/US8454962B2/en not_active Expired - Fee Related
- 2012-09-12 HK HK12108929.5A patent/HK1168116A1/xx unknown
-
2013
- 2013-04-22 US US13/867,498 patent/US8871490B2/en active Active
-
2014
- 2014-02-18 CL CL2014000401A patent/CL2014000401A1/es unknown
- 2014-02-18 CL CL2014000400A patent/CL2014000400A1/es unknown
- 2014-03-06 JP JP2014043790A patent/JP5775615B2/ja active Active
- 2014-04-08 IL IL232008A patent/IL232008A/en active IP Right Grant
- 2014-04-08 IL IL232009A patent/IL232009A/en active IP Right Grant
- 2014-09-26 US US14/497,883 patent/US9499620B2/en active Active
-
2015
- 2015-07-03 JP JP2015134473A patent/JP5980384B2/ja active Active
- 2015-07-16 IL IL239965A patent/IL239965A/en active IP Right Grant
-
2016
- 2016-11-09 US US15/347,233 patent/US20170275365A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JO3615B1 (ar) | جسم مضاد كعامل نوعي تجاه الدايمر ألفا -4- بيتا-7-غير المتجانس | |
| PH12014502527A1 (en) | St2 antigen binding proteins | |
| PH12013502205A1 (en) | Antibodies to il-6 and their uses | |
| MX2012009175A (es) | Metodos para identificar y aislar celulas que expresan un polipeptido. | |
| CL2014000699A1 (es) | Proteina de union al antigeno cd27l; acido nucleico que la codifica; vector de expresion; celula huesped recombinante; composicion que la comprende; su uso para tratar cancer, trastornos autoinmunitarios o inflamatorios; y metodo para elaborar un conjugado anticuerpo cd27l-farmaco. | |
| MX2015008446A (es) | Composiciones de proteinas de union multivalentes. | |
| IL222507A0 (en) | Heterodimeric antibody fc-containing proteins and methods for production thereof | |
| MX2013013832A (es) | Proteínas de unión receptoras fc. | |
| ZA201207211B (en) | Antibodies with ph dependent antigen binding | |
| WO2010145792A8 (en) | Bispecific antigen binding proteins | |
| HK1215954A1 (zh) | 蛋白、核酸、和抗體及其用途 | |
| EP2566890A4 (en) | ANTI-PAI-1 ANTIBODIES AND METHOD FOR THEIR USE | |
| EP2525822A4 (en) | IMMUNOREGULATION WITH ANTI-ILT5 ANTIBODIES AND ILT5-BINDING ANTIBODY FRAGMENTS | |
| BRPI1016204A2 (pt) | proteínas de fusão de anticorpos com sítios de ligação fcrn modificados | |
| GB201003701D0 (en) | System for the expression of a protein | |
| WO2013181576A3 (en) | Methods of evaluating and making biologics | |
| WO2010136483A3 (en) | Antigen-binding proteins | |
| PH12015500751A1 (en) | Anti-her3/her4 antigen binding proteins binding to the beta-hairpin of her3 and beta-hairpin of her4 | |
| EP2496608A4 (en) | FUSION PROTEIN SPECIFICALLY BINDING TO A CONSTANT REGION OF ANTIBODY, PREPARATION THEREFOR, AND METHOD OF ISOLATING ANTIBODY USING THE SAME | |
| UA104311C2 (ru) | Антитело-антагонист, специфическое для гетеродимера альфа-4-бета-7 | |
| IL266073B (en) | Heterodimeric antibody fccontaining proteins and methods for production thereof | |
| EP2540742A4 (en) | MONOCLONAL ANTIBODIES OF ANTI-CYR61 PROTEIN AND USES THEREOF |